Use of Factor VIIa or Factor VIIa Equivalents for Preventing or Attenuating Haemorrhage Growth, and/or Oedema Generation Following Intracerebral Haemorrhage (ICH) in Patients Treated with Antiplatelet Therapy
AssigneeNovo Nordisk HealthCare A/G
InventorsNikolai Constantin Brun, Brett E. Skolnick, Kamilla Begtrup
Life of this patent
Estimating the term…
Abstract
The invention relates to the use of Factor VIIa or a Factor VIIa equivalent for the manufacture of a medicament for preventing complications in ICH patients treated with antiplatelet therapy.
Claims20
A method for preventing or attenuating one or more complications of intracerebral haemorrhage (ICH) in a patient, said method comprising administering to a patient in need thereof an effective amount of a first coagulation agent comprising Factor VIIa or a Factor VIIa equivalent, wherein the patient had received antiplatelet therapy prior to administration of the Factor VIIa or Factor VIIa equivalent.
A method for preventing or attenuating one or more complications of ICH in a majority of ICH patients who have previously received antiplatelet therapy, which is carried out by:
- (i) administering to a group of such ICH patients an amount effective for achieving the prevention or attenuation of Factor VIIa or a Factor VIIa equivalent;
- and (ii) observing a reduction in the frequency of occurrence of one or more complications of ICH among the group of patients who received Factor VIIa or a Factor VIIa equivalent relative to the frequency of occurrence of said complications that would have been expected in the same group of patients who had not received said Factor VIIa or Factor VIIa equivalent.
20-37. (canceled)
Dependencies are inferred from the claim text.